Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Oct;119(3):471–478. doi: 10.1111/j.1476-5381.1996.tb15696.x

Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3.

E Delpy 1, H Coste 1, A C Gouville 1
PMCID: PMC1915707  PMID: 8894166

Abstract

1. In rat aortic rings precontracted with phenylephrine, the beta-adrenoceptor agonist isoprenaline (10 nM to 30 microM) produces greater relaxant effects in preparations with endothelium than in endothelium-denuded preparations. The aim of this study was to determine the mechanisms involved in this effect and in particular investigate the possibility of a synergistic action between adenosine 3':5'-cyclic monophosphate (cyclic AMP) and guanosine 3':5'-cyclic monophosphate (cyclic GMP). 2. Isoprenaline-induced relaxation of rat aortic rings precontracted with phenylephrine was greatly reduced by the nitric oxide (NO) synthase inhibitor N omega-nitro-L-arginine methyl ester (L-NAME, 300 microM) or the soluble guanylate cyclase inhibitors methylene blue (10 microM) or IH-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10 microM) but unaffected by indomethacin (10 microM), a cyclo-oxygenase inhibitor. Similarly, in intact rings, the concentration-response curve of forskolin (10 nM to 1 microM) was shifted to the right upon endothelium removal or treatment with methylene blue. 3. In endothelium-denuded rat aortic rings, isoprenaline-induced relaxation was potentiated by the guanylate cyclase activators atrial natriuretic factor (ANF, 1 to 10 nM) and sodium nitroprusside (SNP, 1 to 10 nM), and to a greater extent in the presence of the cyclic GMP-specific phosphodiesterase (PDE 5) inhibitor, 1,3dimethyl-6-(2-propoxy-5-methane sulphonylamidophenyl) pyrazolo [3,4-d] pyrimidin-4-(5H)-one (DMPPO, 30 nM). Relaxation induced by isoprenaline was also potentiated by the cyclic GMP-inhibited PDE (PDE 3) inhibitor cilostamide (100 nM). 4. Intracellular cyclic nucleotide levels were measured either in rat cultured aortic smooth muscle cells or in de-endothelialized aortic rings. In both types of preparation, isoprenaline (5 nM and 10 microM) increased cyclic AMP levels and this effect was potentiated by cilostamide (10 microM), by rolipram, a cyclic AMP-specific PDE (PDE 4) inhibitor (10 microM) and by cyclic GMP-elevating agents (50 nM ANF or 30 nM SNP plus 100 nM DMPPO). In isoprenaline-stimulated conditions, the increase in cyclic AMP induced by rolipram was further potentiated by cilostamide and by cyclic GMP-elevating agents. Cilostamide and cyclic GMP-elevating agents did not potentiate each other, suggesting a similar mechanism of action. 5. We conclude that in vascular smooth muscle (VSM) cells an increase in cyclic GMP levels may inhibit PDE 3 and, thereby, cyclic AMP catabolism. Under physiological conditions of constitutive NO release, and to a greater extent in the presence of the PDE 5 inhibitor DMPPO, cyclic GMP should act synergistically with adenylate cyclase activators to relax VSM.

Full text

PDF
471

Images in this article

476Figure 8
on p.476

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anand-Srivastava M. B., Trachte G. J. Atrial natriuretic factor receptors and signal transduction mechanisms. Pharmacol Rev. 1993 Dec;45(4):455–497. [PubMed] [Google Scholar]
  2. Buxton I. L., Brunton L. L. Compartments of cyclic AMP and protein kinase in mammalian cardiomyocytes. J Biol Chem. 1983 Sep 10;258(17):10233–10239. [PubMed] [Google Scholar]
  3. Chamley J. H., Campbell G. R., McConnell J. D., Gröschel-Stewart U. Comparison of vascular smooth muscle cells from adult human, monkey and rabbit in primary culture and in subculture. Cell Tissue Res. 1977 Feb 14;177(4):503–522. doi: 10.1007/BF00220611. [DOI] [PubMed] [Google Scholar]
  4. Cornwell T. L., Lincoln T. M. Regulation of intracellular Ca2+ levels in cultured vascular smooth muscle cells. Reduction of Ca2+ by atriopeptin and 8-bromo-cyclic GMP is mediated by cyclic GMP-dependent protein kinase. J Biol Chem. 1989 Jan 15;264(2):1146–1155. [PubMed] [Google Scholar]
  5. Coste H., Grondin P. Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem Pharmacol. 1995 Nov 9;50(10):1577–1585. doi: 10.1016/0006-2952(95)02031-4. [DOI] [PubMed] [Google Scholar]
  6. Fredholm B. B., Sollevi A. Cardiovascular effects of adenosine. Clin Physiol. 1986 Feb;6(1):1–21. doi: 10.1111/j.1475-097x.1986.tb00139.x. [DOI] [PubMed] [Google Scholar]
  7. Garbers D. L. Guanylate cyclase, a cell surface receptor. J Biol Chem. 1989 Jun 5;264(16):9103–9106. [PubMed] [Google Scholar]
  8. Gerzer R., Hofmann F., Schultz G. Purification of a soluble, sodium-nitroprusside-stimulated guanylate cyclase from bovine lung. Eur J Biochem. 1981 Jun 1;116(3):479–486. doi: 10.1111/j.1432-1033.1981.tb05361.x. [DOI] [PubMed] [Google Scholar]
  9. Grace G. C., Macdonald P. S., Dusting G. J. Cyclic nucleotide interactions involved in endothelium-dependent dilatation in rat aortic rings. Eur J Pharmacol. 1988 Mar 22;148(1):17–24. doi: 10.1016/0014-2999(88)90449-9. [DOI] [PubMed] [Google Scholar]
  10. Graier W. F., Groschner K., Schmidt K., Kukovetz W. R. Increases in endothelial cyclic AMP levels amplify agonist-induced formation of endothelium-derived relaxing factor (EDRF). Biochem J. 1992 Dec 1;288(Pt 2):345–349. doi: 10.1042/bj2880345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gray D. W., Marshall I. Novel signal transduction pathway mediating endothelium-dependent beta-adrenoceptor vasorelaxation in rat thoracic aorta. Br J Pharmacol. 1992 Nov;107(3):684–690. doi: 10.1111/j.1476-5381.1992.tb14507.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hayes J. S., Brunton L. L., Mayer S. E. Selective activation of particulate cAMP-dependent protein kinase by isoproterenol and prostaglandin E1. J Biol Chem. 1980 Jun 10;255(11):5113–5119. [PubMed] [Google Scholar]
  13. Hohl C. M., Li Q. A. Compartmentation of cAMP in adult canine ventricular myocytes. Relation to single-cell free Ca2+ transients. Circ Res. 1991 Nov;69(5):1369–1379. doi: 10.1161/01.res.69.5.1369. [DOI] [PubMed] [Google Scholar]
  14. Jang E. K., Davidson M. M., Crankshaw D., Haslam R. J. Synergistic inhibitory effects of atriopeptin II and isoproterenol on contraction of rat aortic smooth muscle: roles of cGMP and cAMP. Eur J Pharmacol. 1993 Dec 21;250(3):477–481. doi: 10.1016/0014-2999(93)90038-j. [DOI] [PubMed] [Google Scholar]
  15. Komas N., Lugnier C., Stoclet J. C. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol. 1991 Oct;104(2):495–503. doi: 10.1111/j.1476-5381.1991.tb12457.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kuhn M., Otten A., Frölich J. C., Förstermann U. Endothelial cyclic GMP and cyclic AMP do not regulate the release of endothelium-derived relaxing factor/nitric oxide from bovine aortic endothelial cells. J Pharmacol Exp Ther. 1991 Feb;256(2):677–682. [PubMed] [Google Scholar]
  17. Lincoln T. M., Cornwell T. L., Taylor A. E. cGMP-dependent protein kinase mediates the reduction of Ca2+ by cAMP in vascular smooth muscle cells. Am J Physiol. 1990 Mar;258(3 Pt 1):C399–C407. doi: 10.1152/ajpcell.1990.258.3.C399. [DOI] [PubMed] [Google Scholar]
  18. Lugnier C., Komas N. Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: role in vasodilatation. Eur Heart J. 1993 Nov;14 (Suppl 1):141–148. [PubMed] [Google Scholar]
  19. Lüscher T. F. Endothelium-derived nitric oxide: the endogenous nitrovasodilator in the human cardiovascular system. Eur Heart J. 1991 Nov;12 (Suppl E):2–11. doi: 10.1093/eurheartj/12.suppl_e.2. [DOI] [PubMed] [Google Scholar]
  20. Macdonald P. S., Dubbin P. N., Dusting G. J. Beta-adrenoceptors on endothelial cells do not influence release of relaxing factor in dog coronary arteries. Clin Exp Pharmacol Physiol. 1987 Jun;14(6):525–534. doi: 10.1111/j.1440-1681.1987.tb01508.x. [DOI] [PubMed] [Google Scholar]
  21. Manganiello V. C., Murata T., Taira M., Belfrage P., Degerman E. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys. 1995 Sep 10;322(1):1–13. doi: 10.1006/abbi.1995.1429. [DOI] [PubMed] [Google Scholar]
  22. Maurice D. H., Crankshaw D., Haslam R. J. Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. Eur J Pharmacol. 1991 Jan 10;192(2):235–242. doi: 10.1016/0014-2999(91)90048-u. [DOI] [PubMed] [Google Scholar]
  23. Maurice D. H., Haslam R. J. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol. 1990 May;37(5):671–681. [PubMed] [Google Scholar]
  24. Muller B., Stoclet J. C., Lugnier C. Cytosolic and membrane-bound cyclic nucleotide phosphodiesterases from guinea pig cardiac ventricles. Eur J Pharmacol. 1992 Mar 12;225(3):263–272. doi: 10.1016/0922-4106(92)90028-t. [DOI] [PubMed] [Google Scholar]
  25. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest. 1986 Jul;78(1):1–5. doi: 10.1172/JCI112536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Murray K. J. Cyclic AMP and mechanisms of vasodilation. Pharmacol Ther. 1990;47(3):329–345. doi: 10.1016/0163-7258(90)90060-f. [DOI] [PubMed] [Google Scholar]
  27. Oliva D., Nicosia S. PGI2-receptors and molecular mechanisms in platelets and vasculature: state of the art. Pharmacol Res Commun. 1987 Nov;19(11):735–765. doi: 10.1016/0031-6989(87)90010-5. [DOI] [PubMed] [Google Scholar]
  28. Reeves M. L., Leigh B. K., England P. J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem J. 1987 Jan 15;241(2):535–541. doi: 10.1042/bj2410535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Satake N., Zhou Q., Morikawa M., Inoue M., Shibata S. Potentiating effect of nicorandil, an antianginal agent, on relaxation induced by isoproterenol in isolated rat aorta: involvement of cyclic GMP-inhibitable cyclic AMP phosphodiesterase. J Cardiovasc Pharmacol. 1995 Mar;25(3):489–494. doi: 10.1097/00005344-199503000-00022. [DOI] [PubMed] [Google Scholar]
  30. Sonnenburg W. K., Beavo J. A. Cyclic GMP and regulation of cyclic nucleotide hydrolysis. Adv Pharmacol. 1994;26:87–114. doi: 10.1016/s1054-3589(08)60052-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES